Physician profile
Amy E Quinn
NPI 1629329230
$5,136.33
in general payments reported to CMS, 2019-2025
37 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,093 · 2022: $1,077 · 2023: $1,230 · 2024: $664 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717 · Consulting Fee: $175 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.63 |
| Consulting Fee | $175.00 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $879.44 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $598.13 | 2021-2025 | |
| Amgen INC. | $420.03 | 2021-2025 | Prolia, Repatha, Repatha |
| Pfizer INC. | $316.39 | 2021-2025 | |
| Novo Nordisk INC | $268.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $266.86 | 2021-2025 | Emgality, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $257.28 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Janssen Pharmaceuticals, INC | $203.06 | 2021-2023 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $181.51 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $154.72 | 2021-2025 | Fanapt |
| Axsome Therapeutics, INC. | $127.75 | 2023-2024 | Auvelity |
| Dexcom, INC. | $127.06 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $113.91 | 2021-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.65 | 2022-2023 | Tradjenta, Jardiance |
| Merck Sharp & Dohme LLC | $102.11 | 2021-2023 | Vaxelis, Gardasil 9, Vaxneuvance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.